<SEC-DOCUMENT>0001129928-23-000026-index.html : 20230505 <SEC-HEADER>0001129928-23-000026.hdr.sgml : 20230505 <ACCEPTANCE-DATETIME>20230505101350 ACCESSION NUMBER: 0001129928-23-000026 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230505 DATE AS OF CHANGE: 20230505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ONCOLYTICS BIOTECH INC CENTRAL INDEX KEY: 0001129928 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38512 FILM NUMBER: 23891819 BUSINESS ADDRESS: STREET 1: 804, 322 - 11 AVENUE SW CITY: CALGARY STATE: A0 ZIP: T2R 0C5 BUSINESS PHONE: 4036707380 MAIL ADDRESS: STREET 1: 804, 322 - 11 AVENUE SW CITY: CALGARY STATE: A0 ZIP: T2R 0C5 </SEC-HEADER> <DOCUMENT> <TYPE>6-K <SEQUENCE>1 <FILENAME>q12023form6-k.htm <DESCRIPTION>6-K <TEXT> Document 1 - file: q12023form6-k.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.1 <SEQUENCE>2 <FILENAME>ex991-interimfsmarch312023.htm <DESCRIPTION>EX-99.1 2023 FIRST QUARTER INTERIM FINANCIAL STATEMENTS <TEXT> Document 2 - file: ex991-interimfsmarch312023.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.2 <SEQUENCE>3 <FILENAME>ex992-q12023mda.htm <DESCRIPTION>EX-99.2 2023 FIRST QUARTER MD&A <TEXT> Document 3 - file: ex992-q12023mda.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.3 <SEQUENCE>4 <FILENAME>ex993-q12023certificationx.htm <DESCRIPTION>EX-99.3 Q3 2023 CERTIFICATION CEO <TEXT> Document 4 - file: ex993-q12023certificationx.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.4 <SEQUENCE>5 <FILENAME>ex994-q12023certificationx.htm <DESCRIPTION>EX-99.4 Q3 2023 CERTIFICATION CFO <TEXT> Document 5 - file: ex994-q12023certificationx.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>6 <FILENAME>mdapipelinea.jpg <TEXT> Document 6 - file: mdapipelinea.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>7 <FILENAME>oncolyticslogotaglineblueaa.jpg <TEXT> Document 7 - file: oncolyticslogotaglineblueaa.jpg
</DOCUMENT> </SEC-DOCUMENT>